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Abstract
Mosaic genome-wide paternal uniparental disomy is an infrequently described disorder in which
affected individuals have signs and symptoms that may resemble Beckwith–Wiedemann syn-
drome. In addition, they can develop multiple benign and malignant tumors throughout life. Rou-
tinemolecular diagnosticsmay not detect the (characteristic) low level ofmosaicism, and the diag-
nosis is likely to be missed. Genetic counseling and a life-long alertness for the development of
tumors is indicated.We describe the long diagnostic process of a patient who already had a tumor
at birth and developed multiple tumors in childhood and adulthood. Furthermore, we offer clues
to recognize the entity.
K EYWORDS
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1 INTRODUCTION
Uniparental disomy (UPD) occurs when the two copies of a (part of
a) chromosome are derived from one parent only. If this chromosome
contains imprinted gene(s), this can result in human disease due to loss
of gene function and can lead to congenital anomalies, intellectual dis-
ability, and other health problems.1
If both copies of (a part of) a chromosome are derived from the
father, this is called paternal UPD (patUPD). Five syndromes are asso-
ciated with patUPD: transient neonatal diabetes mellitus (patUDD6),
Beckwith–Wiedemann syndrome (BWS) (patUPD11), Kagami–Ogata
Abbreviations: BAF, B-allele frequency; BWS, Beckwith–Wiedemann syndrome; GOM, gain of methylation; IC, imprinting center; LOM, loss of methylation; MGWpatUPD,mosaic genome-wide
paternal uniparental disomy;MS-MLPA, methylation-specific multiplex ligation-dependent probe amplification; SNP, single-nucleotide polymorphism; UPD, uniparental disomy.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
c© 2019 The Authors. Pediatric Blood & Cancer Published byWiley Periodicals, Inc.
syndrome (patUPD14), Angelman syndrome (patUPD15), and
patUPD20.2
PatUPD of the whole genome is lethal in utero, as it presents as
hydatidiformmole.3 If UPD of thewhole genome is present in amosaic
state, it can be compatible with life. In 1995, mosaic genome-wide
paternal UPD (MGWpatUPD) was first described in a patient with
BWS and a Wilms tumor.4 Since then, 17 additional cases have been
described (Table 1).3,5–17
Here, we describe a female with multiple benign and malig-
nant tumors, occurring at various ages, in whom eventually
MGWpatUPD was diagnosed. We compare the findings in this
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patient with earlier reported individuals and offer clues for
recognition.
2 CASE DESCRIPTION
The index case was the third child of healthy, nonconsanguineous
Dutch parents (aged 32 and 34 years). Weight at birth after 35 weeks
of gestation was 2520 g (P50-75). The placenta was remarkably large,
weighing 1890 g (>P98). Immediately after birth and later during
life, she developed multiple benign tumors (please see Table 2 for an
overview of all tumors). At one year of age, a body asymmetry became
apparent, with the left side being larger. General health was good;
growth and cognition were undisturbed.
She had two children, one of whom was born with tetralogy of
Fallot without other abnormalities. When she was 37 years, a malig-
nant adrenocortical tumor from the right adrenal gland was surgically
removed. At 39 years, she developed a yolk sac tumor in the sacral
region, which could only partly be removed due to massive local inva-
sion. Curative therapy was not possible and she died within a few
months’ time.
Tumor material and peripheral blood were examined using
methylation-specific multiplex ligation-dependent probe amplification
(MS-MLPA) and single-nucleotide polymorphism (SNP) array (please
see Supporting Information for additional information).
3 RESULTS
In 1997, at 19 years of age, diagnostic testing for BWSwas performed
by Southern blot analysis on lymphocytes. No methylation defect was
detected in imprinting centers (IC) 1and IC2.At38yearsof age,methy-
lation studies IC1 and IC2 were repeated using MS-MLPA on lympho-
cytes, which seemingly showed again a normal methylation of IC1 and
IC2 (Supporting Information Figure S2a).
Because of her subsequent malignancy at age 39, her laboratory
results were reevaluated because of the clinical suspicion of MGW-
patUPD. Reevaluation of the previously performed MS-MLPAME030
(BWS/SRS) did demonstrate a low mosaicism around the detection
level of the technique. This was confirmed by SNP array analysis in
blood, which showed an apparent normal female profile (Supporting
Information Figure S3a), with an aberrant broadening of the B-allele
frequency (BAF) around the 0.5 line fitting low-level percentage of
mosaicism.
Subsequent analysis with MS-MLPA ME034 (MLID) showed a low
mosaic loss of methylation (LOM) of all tested maternally methylated
loci and low mosaic gain of methylation (GOM) of all tested paternally
methylated loci (Supporting Information Figure S2b), indicative for a
lowmosaicMGWpatUPD.
Subsequently, MS-MLPA of DNA isolated from frozen adrenocorti-
cal tumor (Supporting Information Figure S2c and d) showed 80% loss
of maternal methylation, and SNP array analysis in the same material
showed an aberrant BAF pattern for the complete genome (Support-
ing Information Figure S3b). Both strongly suggest a high level (±95%)
MGWpatUPD in the tumor. SNP array analysis of the yolk sac tumor
material from the sacral region showed a similar aberrant BAF profile,
andmany gains and losses of (large parts of) chromosomes (Supporting
Information Figure S3c).
Results were discussed with the patient and her family, explaining
that this de novo genomic imbalance was most likely the cause of her
asymmetry and recurrent tumors, and that this implies no increased
cancer risks for her offspring and other relatives.
4 DISCUSSION
The occurrence of several tumors and asymmetrical body growth as
present in the index case can be associated with MGWpatUPD. The
initial methylation studies, 20 years ago, could not establish this diag-
nosis, as the level of mosaicism for the UPD was below the detec-
tion threshold of themethylation test. Sensitivity of diagnostic genetic
tests has improved since then. Still, even today sensitivity of testing is
not complete, which should be taken into account in evaluating results
of such testing in the light of a suspected clinical diagnosis.
In patientswithMGWpatUPD, theBWSphenotype is predominant;
in individuals with a BWS phenotype, an MGWpatUPD might remain
unrecognized if methylation analyses are restricted to a single UPD
region, e.g., 11p15.18,19 To check for this, methylation tests at various
loci should be undertaken if methylation testing for 11p15 is sugges-
tive for patUPD (loss LIT1andgainH19).Due to themosaicism, aberra-
tions may not be detectable in DNA derived from leucocytes, so other
tissues may need to be studied to proveMGWpatUPD.
The presented patient is the oldest reported individual with an
MGWpatUPD; the other patients range in age from 1 month to 30
years (Table 1).3–17 Obviously, all patients are female, as an androge-
netic lineage (containing two Y chromosomes and no X chromosome)
is not viable.
The predominance of the BWSphenotypemay, in part, be explained
by the mosaic distribution of the UPD. Signs and symptoms in a partic-
ular tissue may occur only if the mosaicism reaches a threshold level,
which can differ between tissues within the same patient. Until now,
this has not been studied in detail. Paternal UPDs of chromosomes 6,
14, 15, and 20 have been reported only in a nonmosaic state.18 Pater-
nal UPD11 has been demonstrated to occur only in a mosaic state,
leading to BWS.19 Likely, tissue-specific effects of imprinted genes
allow low-level mosaic paternal UPD11 to cause signs and symptoms,
and inhibits symptoms of the other low-level mosaic paternal UPDs.13
Fifteen of 19 patients (79%) previously reported with MGW-
patUPD developed tumors, and 12 of them developed more than
a single tumor (Table 2). The four patients in whom no tumor was
described were < 13.5 years. Four of the seven women aged 17 years
or older had breast fibroadenomas. The variability of the nature of the
tumors and the age at which these develop hampers effective surveil-
lance.We suggest general life-long vigilance in individuals withMGW-
patUPD, because more targeted surveillance seems not well possi-
ble. The true frequency of developing tumors in patients with MGW-
patUPD remains uncertain due to the (likely) ascertainment bias in
reported individuals.
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TABLE 2 Occurrence and tumor spectrum in patients withMGWpatUPD
Patients
Age
(years) Tumors
Age
(years)
MGWpatUPD
percentage M/B
This report 39 Fibroepithelial polypmandible left 0 B
Liver hemangioma 0 B
Tumor umbilicus; not further classified 1 B
Breast fibroadenoma left 17 B
Breast fibroadenoma left 17 B
Breast fibroadenoma left 35 B
Adrenocortical tumor right adrenal gland; biphasic epithelial/mesenchymal
tumor, either yolk sac tumor or clear-cell carcinoma
36 95% M
Adrenocortical tumor left adrenal gland 37 M
Yolk sac tumor sacral region 39 95% M
Romanelli9 30 Wilms tumor 4.4 M
Adrenocortical virilizing adenoma 20 86% M
Melanocytic nevus right mandibular region 27 M
Pancreatic adenocarcinoma (ductal) 28.5 M
Liver metastasis 29 M
Ohtsuka14 23 Multiple breast fibroadenomas 16 B
Ovarian adenofibroma 16 B
Multiple breast fibroadenomas 17 B
Bertoin15 21 Bilateral cortical hyperplasia 0.1 B
Virilizing adrenal tumor 16 86% M
Virilizing adrenal tumor recurrence 18 79% M
Virilizing adrenal tumor recurrence 21 94% M
Multiple breast fibroadenomas >21 30% B
Wilson8 21 Pheochromocytoma right adrenal 8 M
Pheochromocytoma left adrenal 9.5 M
Three extra-adrenal paragangliomas (i.e., pheochromocytoma) 15 M
Inbar-
Feigenberg11
20 Paraumbilical hemangioma 0.4 B
Choledochal cyst 0.8 B
Hamartomous tumor heart 13 B
Hepatic cysts B
Gogiel3 18 Liver hamartoma 0.1 B
Steroid cell tumor ovary 12 100% M
Breast fibroadenoma 18 B
Wilson8 14 Cystic adrenomegaly Prenatal B
Hemangioendothelioma 0.4 B
Hepatoblastoma 1.3 M
Pheochromocytoma 11 M
Yamazawa10 13.3 No tumors
Bryke5 10.8 Hepatic hyperplasia 1.5 B
Pheochromocytoma 10.8 M
Kalish13 7 Liver hemangioma 0.1 B
Liver hamartoma 0.1 80% B
Kalish13 6 Bladder polyps 0.1 95% B
Hepatic hemangiomas 0.2 B
Hoban4 4 Wilms tumor 0.9 M
(Continues)
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TABLE 2 (Continued)
Patients
Age
(years) Tumors
Age
(years)
MGWpatUPD
percentage M/B
Giurgea6 4 No tumors
Reed7 2.2 Hepatic mesenchymal hamartoma 0.9 60% M
Hopman17 2 No tumors
Darcy16 0.5 Hepatoblastoma 0.3 M
Wilms tumor 0.5 M
Kalish13 0.3 Adrenocortical hyperplasia 0.2 95% B
Johnson12 0.08 No tumors
Abbreviations: B, benign;M, malignant.
We conclude that in every child or adult, who develops multiple dif-
ferent benign and malignant tumors with one or more signs or symp-
toms fitting a paternal UPD, an imprinting disturbance should be con-
sidered, especially MGWpatUPD. Routine molecular diagnostic pro-
cedures may not be sufficient to detect a low level of mosaicism, and
the clinical suspicion should lead to directed testing inmultiple tissues.
If MGWpatUPD is diagnosed, adequate genetic counseling is possible
and a life-long alertness for developing additional tumors is indicated.
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